News

Biomune Expands Production Facilities

Lenexa, KS—Biomune Company recently announced an expanded production facility which will significantly increase the company’s production capacity. “We are very pleased to begin occupying the new building which is located just across the street from our original facility”, according to Ron Plylar, Biomune president. “The new building will significantly increase recombinant vaccine production capacity and add considerable supplemental production to our Biomune Lenexa campus” he added.

The new facility will give Biomune increased production capacity to keep pace with growing worldwide demand for the company’s vaccines. Construction on the new production facility will continue throughout 2004.

The new facility will boost output of all product lines and is expected to help position the Biomune Company as a worldwide leader in innovative poultry vaccine development and production.

Biomune is a leading U.S. manufacturer of vaccines and bacterins for the poultry industry. Since its inception in 1988, the company’s rapid growth has been marked by technology breakthroughs and new product introductions such as the world’s first licensed Salmonella enteritidis vaccines for poultry that are considered the world’s standard. The company offers a quality line of inactivated, recombinant and live vaccines in addition to custom-made autogenous vaccines in combinations needed for modern poultry production. The company produces over 50 USDA-licensed vaccines and bacterins and serves customers in 37 countries. For further information on the full line of Biomune vaccines and bacterins call 1-800-846-0230 or log on to the company’s web site at www.BiomuneCompany.com